[Clinical studies on cefsulodin in the field of pediatrics].
An anti-P. aeruginosa, cephalosporin, cefsulodin (CFS) was administered to 2 patients who were affected with inveterate urinary tract infection at ages of 1 year 8 months and 2 years, and another with pneumonia combined with lung fibrosis and bronchiectasia at 3 years. The clinical responses in 3 cases were "good" in 2 and "fair" in 1. The bacteriological responses to 3 strains of P. aeruginosa isolated in this clinical study were "eradicated" in 1, "decreased" in 1, and "unchanged" in 1. No side effects were observed.
D000367:Age Factors; D002441:Cefsulodin; D002511:Cephalosporins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D006801:Humans; D007223:Infant; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects
D002511:Cephalosporins; D002441:Cefsulodin